The results of the modified St Jude Total Therapy XV Protocol in the treatment of low- and middle-income children with acute lymphoblastic leukemia

References

• Lato MW, Przysucha A, Grosman S, et al. The new therapeutic strategies in pediatric t-cell acute lymphoblastic leukemia. IJMS. 2021;22(9):4502.
   Google Scholar
• Inaba H, Pui C-H. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. JCM. 2021;10(9):1926.
   Google Scholar
• Kaplan JA. Leukemia in children. Pediatr Rev. 2019;40(7):319–331.
   PubMed Web of Science ®Google Scholar
• Frey NV. Relapsed ALL: CAR T vs transplant vs novel therapies. Hematology Am Soc Hematol Educ Program. 2021;2021(1):1–6.
   PubMedGoogle Scholar
• Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a children’s oncology group report. Leukemia. 2010;24(2):285–297.
   PubMed Web of Science ®Google Scholar
• Maloney KW, Devidas M, Wang C, et al. Outcome in children with Standard-Risk B-Cell acute lymphoblastic leukemia: results of children’s oncology group trial AALL0331. J Clin Oncol. 2020;38(6):602–612.
   PubMed Web of Science ®Google Scholar
• Pui CH, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165–1174.
   PubMed Web of Science ®Google Scholar
• Surapolchai P, Anurathapan U, Sermcheep A, et al. Long-Term outcomes of modified St jude children’s research hospital total therapy XIIIB and XV protocols for thai children with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2019;19(8):497–505.
   PubMed Web of Science ®Google Scholar
• Attarbaschi A, Mann G, Zimmermann M, et al. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia. 2020;34(6):1694–1700.
   PubMed Web of Science ®Google Scholar
• Pui CH, Relling MV, Sandlund JT, et al. Rationale and design of total therapy study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol. 2004;83(Suppl 1):S124–S6.
   PubMedGoogle Scholar
• Quist-Paulsen P, Toft N, Heyman M, et al. T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia. 2020;34(2):347–357.
   PubMed Web of Science ®Google Scholar
• Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199–209.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s oncology group study AALL0031. Leukemia. 2014;28(7):1467–1471.
   PubMed Web of Science ®Google Scholar
• Chen H, Xu L-P, Zhang X-h, et al. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation. Leuk Res. 2022;121:106930.
   PubMed Web of Science ®Google Scholar
• Pui CH, Pei D, Campana D, et al. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia. 2014;28(12):2336–2343.
   PubMed Web of Science ®Google Scholar
• Campana D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr Opin Hematol. 2012;19(4):313–318.
   PubMed Web of Science ®Google Scholar
• Bader P, Salzmann-Manrique E, Balduzzi A, et al. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 2019;3(21):3393–3405.
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730–2741.
   PubMed Web of Science ®Google Scholar
• Yetgin S, Tuncer MA, Cetin M, et al. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia. 2003;17(2):328–333.
   PubMed Web of Science ®Google Scholar
• Klastersky J, De Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111–v118.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Averbuch D, Castagnola E, et al. 8th european conference on infections in leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021;22(6):e270–e280.
   PubMed Web of Science ®Google Scholar
• Gao YJ, Lu FJ, Wang HS. Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: the experience of a single children’s hospital in China. J Pediatr Hematol Oncol. 2006;28(12):798–802.
   PubMed Web of Science ®Google Scholar
• Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a Resource-Poor area. JAMA. 2004;291(20):2471–2475.
   PubMed Web of Science ®Google Scholar
• Abboud MR, Ghanem K, Muwakkit S. Acute lymphoblastic leukemia in low and Middle-income countries: disease characteristics and treatment results. Curr Opin Oncol. 2014;26(6):650–655.
   PubMed Web of Science ®Google Scholar
• Gupta S, Hunger SP. Recent trends in the results of studies conducted by the children’s oncology group acute lymphoblastic leukemia committee and implications for emerging cooperative trial groups in low- and Middle-income countries. Pediatric Hematology Oncology Journal. 2020;5(4):151–155.
   Google Scholar
• Ceppi F, Antillon F, Pacheco C, et al. Supportive medical care for children with acute lymphoblastic leukemia in low- and Middle-income countries. Expert Rev Hematol. 2015;8(5):613–626.
   PubMed Web of Science ®Google Scholar
• Ghafoor T, Anwarullah AI, et al. Pediatric Acute Lymphoblastic Leukemia; Clinical Characteristics, Treatment Outcome, and prognostic factors; Ten Years’ Experience from A Low- and Middle-Income Country. Authorea Preprints; 2022.
   Google Scholar
• Gupta S, Yeh S, Martiniuk A, et al. The magnitude and predictors of abandonment of therapy in paediatric acute leukaemia in Middle-income countries: a systematic review and meta-analysis. Eur J Cancer. 2013;49(11):2555–2564.
   PubMed Web of Science ®Google Scholar
• Kakaje A, Alhalabi MM, Ghareeb A, et al. Rates and trends of childhood acute lymphoblastic leukaemia: an epidemiology study. Sci Rep. 2020;10(1):6756.
   PubMed Web of Science ®Google Scholar
• Shen S, Cai J, Chen J, et al. Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China. Hematol Oncol. 2018;36(4):679–688.
   PubMed Web of Science ®Google Scholar
• Gupta S, Teachey DT, Chen Z, et al. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a children’s oncology group report. Cancer. 2022;128(9):1863–1870.
   PubMed Web of Science ®Google Scholar
• Sutton R, Venn NC, Tolisano J, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol. 2009;146(3):292–299.
   PubMed Web of Science ®Google Scholar
• Jeha S, Choi J, Roberts KG, et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease–directed therapy. Blood Cancer Discov. 2021;2(4):326–337.
   PubMedGoogle Scholar
• Jovanovska A, Martinova K, Kocheva S, et al. Clinical significance of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Open Access Maced J Med Sci. 2019; Sep 157(17):2818–2823.
   PubMedGoogle Scholar
• Shen Z, Gu X, Mao W, et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18(1):755.
   PubMedGoogle Scholar
• Pui CH, Pei D, Sandlund JT, et al. Long-term results of St jude total therapy studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):371–382.
   PubMed Web of Science ®Google Scholar
• Seif AE, Fisher BT, Li Y, et al. Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61(5):846–852.
   PubMed Web of Science ®Google Scholar
• Khan MI, Naseem L, Manzoor R, et al. Mortality analysis in children during induction therapy for acute lymphoblastic leukemia. JIMDC. 2017;6(2):69–72.
   Google Scholar
• Lund B, Åsberg A, Heyman M, et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2011;56(4):551–559.
   PubMed Web of Science ®Google Scholar
• Kiem Hao T, Nhu Hiep P, Kim Hoa NT, et al. Causes of death in childhood acute lymphoblastic leukemia at hue Central hospital for 10 years (2008-2018). Glob Pediatr Health. 2020;7:2333794X20901930.
   PubMedGoogle Scholar
• Koc A, Aycicek A, Ozdemir ZC, et al. Outcome of modified St jude total therapy 13A for childhood acute lymphoblastic leukemia in the southeast region of Turkey. J Pediatr Hematol Oncol. 2013;35(1):36–41.
   PubMedGoogle Scholar
• Öztürk AP, Koç B, Zülfikar B. Acute complications and survival analysis of childhood acute lymphoblastic leukemia: a 15-year experience. Clin Lymphoma Myeloma Leuk. 2021;21(1):e39–e47.
   PubMed Web of Science ®Google Scholar